It’s hard enough coping with recurrent migraine attacks. Add suffering from depression and it’s nearly impossible to function.
We’re researching a marketed medication to see if it can prevent migraine in people with major depressive disorder. Join us.
The study is evaluating an investigational drug called fremanezumab in adults with migraine and major depressive disorder (MDD). Fremanezumab is currently approved in several countries for the prevention of migraine, but it is not approved for treating MDD.
You may qualify to participate if you:
• Are 18 to 70 years of age
• Experience migraines, and:
– the migraines started before age 50
– have 4 or more migraine days within a month
• Are either not using or using no more than 1 migraine preventive medication (e.g., topiramate)
• Are diagnosed with moderate or severe Major Depressive Disorder for at least the past year. If taking medication for MDD, you must be on a stable dose for the last 2 months.
Other criteria will be reviewed to determine if you qualify for this study.
Participation in the study will last approximately 7 months and will require about 6 visits to the research clinic. The study drug, clinic visits, laboratory tests, and procedures that are part of the study will be provided at no cost. You may also be compensated for your study-related travel expenses.
For more information, please call 617-744-1310 or send us an email.
Also, please visit our website at www.MedVadis.com.
Share our link on social media: www.whyclinical.com